Mutation-associated transcripts reconstruct the prognostic features of oral tongue squamous cell carcinoma

Abstract

Tongue squamous cell carcinoma is highly malignant and has a poor prognosis. In this study, we aimed to combine whole-genome sequencing, whole-genome methylation, and whole-transcriptome analyses to understand the molecular mechanisms of tongue squamous cell carcinoma better. Oral tongue squamous cell carcinoma and adjacent normal tissues from five patients with tongue squamous cell carcinoma were included as five paired samples. After multi-omics sequencing, differentially methylated intervals, methylated loop sites, methylated promoters, and transcripts were screened for variation in all paired samples. Correlations were analyzed to determine biological processes in tongue squamous cell carcinoma. We found five mutated methylation promoters that were significantly associated with mRNA and lncRNA expression levels. Functional annotation of these transcripts revealed their involvement in triggering the mitogen-activated protein kinase cascade, which is associated with cancer progression and the development of drug resistance during treatment. The prognostic signature models constructed based on WDR81 and HNRNPH1 and combined clinical phenotype–gene prognostic signature models showed high predictive efficacy and can be applied to predict patient prognostic risk in clinical settings. We identified biological processes in tongue squamous cell carcinoma that are initiated by mutations in the methylation promoter and are associated with the expression levels of specific mRNAs and lncRNAs. Collectively, changes in transcript levels affect the prognosis of tongue squamous cell carcinoma patients.

References

[1.] Bello, I. O., Soini, Y. & Salo, T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral Oncol. 46, 630–635 (2010).

[2.] Khowal S, Naqvi SH, Monga S, Jain SK, Wajid S. Assessment of cellular and serum proteome from tongue squamous cell carcinoma patient lacking addictive proclivities for tobacco, betel nut, and alcohol: case study. J. Cell Biochem., 2018, 119: 5186-5221.

[3.] Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res., 1998, 18: 4779-4786.

[4.] van Monsjou, H. S., Wreesmann, V. B., van den Brekel, M. W. & Balm, A. J. Head and neck squamous cell carcinoma in young patients. Oral Oncol. 49, 1097–1102 (2013).

[5.] Paderno A, Morello R, Piazza C. Tongue carcinoma in young adults: a review of the literature. Acta Otorhinolaryngol. Ital., 2018, 38: 175-180.

[6.] Reuter, J. A., Spacek, D. V., Snyder, M. P. High-throughput sequencing technologies. Mol. Cell. 58, 586–597 (2015).

[7.] Sharma, S., Kelly, T. K. & Jones, P. A. Epigenetics in cancer. Carcinogenesis 31, 27–36 (2010).

[8.] Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 2002, 3: 415-428.

[9.] Li Y, . Serum circulating human mRNA profiling and its utility for oral cancer detection. J. Clin. Oncol., 2006, 24: 1754-1760.

[10.] Zhang H, . Long non-coding RNA HOTTIP is correlated with progression and prognosis in tongue squamous cell carcinoma. Tumor Biol., 2015, 36: 8805-8809.

[11.] Kong XP, . The expression and functional role of a FOXC1 related mRNA-lncRNA pair in oral squamous cell carcinoma. Mol. Cell Biochem., 2014, 394: 177-186.

[12.] Tang HK, Wu ZY, Zhang JP, Su B. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol. Med. Rep., 2013, 7: 761-766.

[13.] Li YF, . DNA methylation profiles and biomarkers of oral squamous cell carcinoma. Epigenetics-Us, 2015, 10: 229-236.

[14.] Jia, L. F. et al. Expression, regulation and roles of miR‐26a and MEG3 in tongue squamous cell carcinoma. Int. J. Cancer 135, 2282–2293 (2014).

[15.] Jiang L, . Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. Hum. Genet., 2011, 129: 189-197.

[16.] Zhang, K., Wang, Q., Zhong, B. & Gong, Z. LUCAT1 as an oncogene in tongue squamous cell carcinoma by targeting miR‐375 expression. J. Cell. Mol. Med. 25, 4543–4550 (2021).

[17.] Poonam, R. Clinicopathological correlation of tumor-stroma ratio and inflammatory cell infiltrate with tumor grade and lymph node metastasis in squamous cell carcinoma of buccal mucosa and tongue in 41 cases with review of literature. J. Cancer Res. Ther. 16, 445–451 (2020).

[18.] Khadijah, M. Meta-analysis on risk factors of squamous cell carcinoma of the tongue in young adults. J. Oral Maxillofacial Pathol. JOMFP 23, 450–457 (2019).

[19.] Maura L G. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl Cancer Inst., 2008, 100: 407-420.

[20.] McKay MM. Integrating signals from RTKs to ERK/MAPK. Oncogene, 2007, 26: 3113-3121.

[21.] David L. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell. Mol. Life Sci.: CMLS, 2016, 73: 4397-4413.

[22.] Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell, 2000, 103: 239-252.

[23.] András Z. JNK signaling: regulation and functions based on complex protein-protein partnerships. Microbiol. Mol. Biol. Rev.: MMBR, 2016, 80: 793-835.

[24.] Michael WP. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep., 2014, 15: 1243-1253.

[25.] FuiBoon K. The extracellular matrix modulates the metastatic journey. Dev. Cell, 2019, 49: 332-346.

[26.] Paolo PP. Collagen density promotes mammary tumor initiation and progression. BMC Med., 2008, 6

[27.] Caroline B. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol., 2014, 15: 786-801.

[28.] Wenting X. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adhes. Migr., 2015, 9: 317-324.

[29.] Junli D. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer, 2019, 19

[30.] Jiaen W. Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy. Biomedicine Pharmacother. = Biomedecine pharmacotherapie, 2020, 129: 110484.

[31.] Kian K. A. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med., 2010, 363: 24-35.

[32.] Ashley, H. Targeted therapy in oropharyngeal squamous cell carcinoma: the implications of HPV for therapy. Rare Cancers Ther. 3, 89–117 (2015).

[33.] Nadine H. Crosstalk between calcium and reactive oxygen species signaling in cancer. Cell Calcium, 2017, 63: 70-96.

[34.] Sarah J, R.-T. The calcium-signaling toolkit in cancer: remodeling and targeting. Cold Spring Harbor Perspect. Biol. 11, a035204 (2019).

[35.] Peng C. Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis. Signal Transduct. Target. Ther., 2020, 5: 51.

[36.] Liu, Y. W., Tu, H. Y., Zhang, L. L., Xiong, J. P. & Li, L. FOXP3-induced LINC00885 promotes the proliferation and invasion of cervical cancer cells. Mol. Med. Rep. 23, https://doi.org/10.3892/mmr.2021.12097 (2021).

[37.] Liu, Y. L., Chen, J. R., Zhou, L. Z. & Yin, C. H. LINC00885 promotes cervical cancer progression through sponging miR-3150b-3p and upregulating BAZ2A. Biol. Direct 17, https://doi.org/10.1186/s13062-021-00314-6 (2022).

[38.] Abba, M. C. et al. LINC00885 a novel oncogenic long non-coding RNA associated with early stage breast cancer progression. Int. J. Mol. Sci. 21 https://doi.org/10.3390/ijms21197407 (2020).

[39.] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15

[40.] M., C. org.Hs.eg.db: Genome wide annotation for human. (2015).

[41.] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics, 2012, 16: 284-287.

[42.] Lin H, Zelterman D. Modeling survival data: extending the Cox model. Technometrics, 2000, 44: 85-86.

[43.] Therneau T. A package for survival analysis. R. Package, 2012, 2: 37-2.

[44.] Kassambara, A. Drawing survival curves using ‘ggplot2’ [R package survminer version 0.2.0]. (2017).

[45.] Ginestet C. ggplot2: elegant graphics for data analysis. J. R. Stat. Soc. Stat., 2011, 174: 245-245.

[46.] ggpubr: ‘ggplot2’ based publication ready plots. (2017).

[47.] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 2010, 26: 139-140.

[48.] Li JCA. Modeling survival data: extending the Cox model. Socio. Method Res., 2003, 32: 117-120.

[49.] Friedman, J. H., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1 (2010).

[50.] Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox’s proportional hazards model via coordinate descent. J. Stat. Softw., 2011, 39: 1-13.

[51.] Kassambara, A., Kosinski, M. & Biecek, P. survminer: drawing survival curves using ‘ggplot2’. (2016).

[52.] Heagerty, P. J. survivalROC: time-dependent ROC curve estimation from censored survival data. (2013).

[53.] Gordon, M. & Lumley, T. forestplot: advanced forest plot using ‘grid’ graphics. (2016).

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81772275, 32071462)